Q1 EPS Estimate for IDEXX Laboratories Decreased by Analyst

IDEXX Laboratories, Inc. (NASDAQ:IDXX) – Analysts at Leerink Partnrs lowered their Q1 2025 earnings estimates for IDEXX Laboratories in a research report issued to clients and investors on Monday, February 3rd. Leerink Partnrs analyst D. Clark now expects that the company will post earnings per share of $2.77 for the quarter, down from their prior forecast of $3.10. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for IDEXX Laboratories’ current full-year earnings is $10.45 per share. Leerink Partnrs also issued estimates for IDEXX Laboratories’ Q2 2025 earnings at $3.22 EPS, Q3 2025 earnings at $3.04 EPS, Q4 2025 earnings at $2.84 EPS, FY2025 earnings at $11.86 EPS, FY2026 earnings at $13.80 EPS, FY2027 earnings at $15.40 EPS and FY2028 earnings at $17.17 EPS.

Several other analysts also recently weighed in on the company. Stifel Nicolaus dropped their price objective on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research report on Thursday, October 10th. JPMorgan Chase & Co. dropped their target price on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a report on Friday, October 11th. Bank of America lifted their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday. StockNews.com downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday. Finally, Piper Sandler restated a “neutral” rating and issued a $435.00 target price (down previously from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $524.38.

IDEXX Laboratories Trading Up 0.8 %

Shares of IDXX stock opened at $468.55 on Thursday. IDEXX Laboratories has a fifty-two week low of $398.50 and a fifty-two week high of $583.39. The stock’s fifty day moving average price is $425.88 and its two-hundred day moving average price is $453.51. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42. The company has a market cap of $38.37 billion, a PE ratio of 45.18, a P/E/G ratio of 3.64 and a beta of 1.37.

Insider Buying and Selling

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the sale, the director now owns 905 shares of the company’s stock, valued at approximately $380,498.20. This represents a 27.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.18% of the stock is currently owned by insiders.

Institutional Investors Weigh In On IDEXX Laboratories

A number of institutional investors have recently modified their holdings of IDXX. Algert Global LLC grew its holdings in IDEXX Laboratories by 70.0% during the 2nd quarter. Algert Global LLC now owns 709 shares of the company’s stock worth $345,000 after acquiring an additional 292 shares during the period. Sanctuary Advisors LLC bought a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at about $1,363,000. Czech National Bank grew its stake in IDEXX Laboratories by 6.5% during the third quarter. Czech National Bank now owns 16,766 shares of the company’s stock worth $8,471,000 after purchasing an additional 1,028 shares during the period. GAMMA Investing LLC increased its holdings in IDEXX Laboratories by 26.8% in the third quarter. GAMMA Investing LLC now owns 1,484 shares of the company’s stock worth $750,000 after purchasing an additional 314 shares in the last quarter. Finally, Mather Group LLC. lifted its stake in IDEXX Laboratories by 3.9% in the third quarter. Mather Group LLC. now owns 617 shares of the company’s stock valued at $312,000 after buying an additional 23 shares during the period. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.